Ozempic vs Mounjaro in South Africa: Which Weight Loss Injection Actually Works Better?
If you are considering a GLP-1 weight loss injection in South Africa, two names dominate the conversation: Ozempic (semaglutide) and Mounjaro (tirzepatide). Both suppress appetite, both cause significant weight loss, and both require weekly injections. But they are not the same drug, they do not work the same way, and they are not equally available in South Africa.
This is a straightforward head-to-head comparison covering what the clinical trial data actually shows, what each costs in ZAR, and which one you can realistically get from a South African pharmacy today.
Quick Comparison: Ozempic vs Mounjaro at a Glance
| Feature | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Drug class | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Available doses | 0.25mg, 0.5mg, 1mg, 2mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Average weight loss | ~12-15% body weight | ~20-22% body weight (highest dose) |
| SA availability | SAHPRA approved, widely available | Limited (Section 21 access) |
| Monthly cost (ZAR est.) | R3,000-R4,500 | R5,000-R7,000 |
| Medical aid coverage | Covered by most plans (conditions apply) | Limited/no coverage currently |
How They Work: One Pathway vs Two
The fundamental difference between these drugs is their mechanism of action.
Ozempic: GLP-1 Only
Ozempic contains semaglutide, which mimics the natural hormone GLP-1 (glucagon-like peptide-1). When you inject semaglutide, it:
- Suppresses appetite by acting on GLP-1 receptors in the hypothalamus
- Slows gastric emptying so food stays in your stomach longer and you feel full faster
- Improves insulin sensitivity and reduces blood sugar levels
- Reduces food reward by dampening the brain's pleasure response to high-calorie food
This is a single-pathway approach. It works well -- clinical trials consistently show 12-15% average body weight loss -- but it only targets one hormone receptor system.
Mounjaro: GLP-1 + GIP (Dual Agonist)
Mounjaro contains tirzepatide, which activates two receptor systems simultaneously:
- GLP-1 receptors -- same appetite suppression and gastric emptying effects as Ozempic
- GIP receptors (glucose-dependent insulinotropic polypeptide) -- enhances insulin secretion, improves fat metabolism, and may increase energy expenditure. GIP also appears to work synergistically with GLP-1 to produce greater appetite suppression than either hormone alone.
This dual-agonist approach is why tirzepatide consistently outperforms semaglutide in clinical trials. Two hormonal pathways working together produce a stronger combined effect than one pathway alone, regardless of dose.
Weight Loss Results: What the Clinical Trials Show
This is the comparison most people want to see. Below are results from the pivotal Phase 3 trials for each drug -- STEP trials for semaglutide and SURMOUNT trials for tirzepatide.
| Trial | Drug & Dose | Duration | Average Weight Loss | Patients Losing 20%+ |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg (Wegovy dose) | 68 weeks | ~14.9% | ~32% |
| SURMOUNT-1 | Tirzepatide 5mg | 72 weeks | ~15% | ~27% |
| SURMOUNT-1 | Tirzepatide 10mg | 72 weeks | ~19.5% | ~46% |
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | ~20.9% | ~57% |
The numbers are clear: tirzepatide at higher doses produces substantially more weight loss than semaglutide. At the 15mg dose, more than half of participants lost over 20% of their body weight -- a threshold that begins to approach the results of bariatric surgery without an operation.
However, context matters. The STEP and SURMOUNT trials used slightly different protocols, patient populations, and timeframes. A direct head-to-head trial (SURMOUNT-5) compared tirzepatide 15mg against semaglutide 2.4mg and confirmed that tirzepatide produced greater weight loss.
What Does This Mean in Kilograms?
For a South African woman weighing 95kg (a common starting weight in obesity treatment):
- Ozempic/Wegovy (semaglutide 2.4mg): ~14.2kg loss over 68 weeks (finishing at approximately 81kg)
- Mounjaro (tirzepatide 15mg): ~19.9kg loss over 72 weeks (finishing at approximately 75kg)
That is a meaningful difference of roughly 5-6kg more weight loss with tirzepatide at the maximum dose.
Side Effects Compared
Both drugs cause gastrointestinal side effects, particularly during the dose-escalation phase (the first 2-3 months when your dose is gradually increased).
| Side Effect | Ozempic/Wegovy | Mounjaro |
|---|---|---|
| Nausea | ~40-44% (most common) | ~25-33% |
| Diarrhoea | ~30% | ~17-23% |
| Vomiting | ~24% | ~12-18% |
| Constipation | ~24% | ~17-20% |
| Injection site reaction | Mild (rare) | Mild (rare) |
| Discontinuation due to side effects | ~5-7% | ~4-7% |
A notable finding: despite producing more weight loss, Mounjaro tends to cause fewer GI side effects than Ozempic in trial data. This may be because the GIP component has a moderating effect on nausea, or because Mounjaro's dose escalation schedule is more gradual. Either way, it is a meaningful advantage -- GI side effects are the primary reason people discontinue GLP-1 medications.
Both drugs carry the same class-level warnings: do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both can potentially cause pancreatitis and gallbladder problems, though these are uncommon. Read our full semaglutide side effects guide for management strategies.
Cost in South Africa (ZAR)
Cost is a major factor for South Africans choosing between these medications, and the difference is significant.
| Medication | Monthly Cost (ZAR est.) | Annual Cost (ZAR est.) | How to Get It |
|---|---|---|---|
| Ozempic 0.5-1mg | R3,000-R4,500 | R36,000-R54,000 | Dis-Chem, Clicks, independent pharmacies |
| Wegovy 2.4mg | R4,000-R6,000 | R48,000-R72,000 | Pharmacies (stock varies) |
| Mounjaro 5-15mg | R5,000-R7,000 | R60,000-R84,000 | Section 21 via doctor only |
Ozempic wins on cost and accessibility. It is roughly R2,000-R2,500 per month cheaper than Mounjaro and available from any pharmacy with a prescription. Mounjaro requires your doctor to submit a Section 21 application to SAHPRA for each individual patient, which adds administrative friction and can take weeks to process.
Availability in South Africa (June 2026)
Ozempic: Widely Available
Ozempic (semaglutide) is SAHPRA-approved and available at major pharmacy chains across South Africa. You can get it with a standard prescription from your GP, endocrinologist, or obesity specialist. Supply has stabilised after the shortages of 2023-2024, though stock levels can still vary by region.
- Dis-Chem: Stocked nationally, both in-store and online
- Clicks: Available at most locations
- Independent pharmacies: Widely distributed
Mounjaro: Limited Access
Mounjaro (tirzepatide) is not yet fully registered with SAHPRA for the obesity indication. South African patients access it through:
- Section 21 applications: Your doctor applies to SAHPRA for permission to prescribe an unregistered medicine for a named patient. This is the main legal pathway currently.
- Specialist obesity clinics: Some private clinics have established supply channels and can facilitate access more quickly.
- Eli Lilly SA: The manufacturer is working toward full SAHPRA registration, but no confirmed date has been announced.
If straightforward access matters to you -- and it should, because consistent dosing is critical for results -- Ozempic is the practical choice in South Africa right now.
Who Should Choose Ozempic?
Ozempic is likely the better choice if:
- You want a medication you can get today from any pharmacy with a standard prescription
- You need medical aid coverage for your weight loss medication
- Budget is a primary concern (R3,000-R4,500/month vs R5,000-R7,000/month)
- You have type 2 diabetes alongside obesity (Ozempic is specifically approved for diabetes management)
- You are starting your first GLP-1 medication and want to see how your body responds before committing to a more expensive option
Who Should Choose Mounjaro?
Mounjaro may be worth pursuing if:
- You have tried Ozempic and plateaued -- your weight loss has stalled and your doctor recommends stepping up to a dual-agonist
- You need to lose a larger percentage of body weight (BMI 40+ or significant obesity-related health conditions)
- You can afford the higher cost out of pocket and are comfortable with the Section 21 process
- You experienced significant nausea on semaglutide and want to try a medication that may cause fewer GI side effects
- Your doctor has access to specialist supply channels and can manage the administrative requirements
Can You Switch From Ozempic to Mounjaro?
Yes, switching is possible and is becoming increasingly common worldwide. Your doctor would typically:
- Confirm you have reached a genuine plateau on your current Ozempic dose (not just a temporary stall)
- Submit a Section 21 application to SAHPRA for tirzepatide
- Start you on the lowest Mounjaro dose (2.5mg) regardless of your previous Ozempic dose
- Titrate up gradually over 4-5 months to the optimal dose
Do not switch medications without medical supervision. The dose-escalation schedule is important for minimising side effects, and your doctor needs to monitor your response.
What About the Next Generation?
Both Ozempic and Mounjaro are excellent medications, but the weight loss drug pipeline is advancing rapidly. Several next-generation drugs may surpass both:
- CagriSema -- Novo Nordisk's GLP-1 + amylin combination showed ~22.7% weight loss in Phase 3 trials (injection)
- Retatrutide -- Eli Lilly's triple-agonist (GLP-1 + GIP + glucagon) produced ~24% weight loss in Phase 2 (injection)
- Survodutide -- Boehringer Ingelheim's dual GLP-1/glucagon agonist also targets fatty liver disease
- Orforglipron and amycretin -- oral pills that could eliminate the need for injections entirely
None of these are available in South Africa yet. For now, the choice is between medications you can access today -- and that means Ozempic vs Mounjaro.
The Bottom Line
Mounjaro produces more weight loss. The clinical data is unambiguous -- tirzepatide's dual mechanism outperforms semaglutide's single mechanism at every comparable timepoint.
Ozempic is the practical choice in South Africa in 2026. It is SAHPRA-approved, widely stocked, covered by medical aids, and costs R2,000+ less per month. For most South Africans beginning GLP-1 treatment, Ozempic is where you start.
If you plateau on Ozempic after 6-12 months and your doctor agrees you would benefit from a dual-agonist, switching to Mounjaro via Section 21 is a reasonable next step. But starting with the accessible, affordable, proven option makes sense for the majority of patients.
Whichever medication you choose, combine it with a high-protein diet (at least 1.2-1.6g protein per kg body weight daily), regular exercise (especially resistance training), and consistent follow-up with your prescribing doctor. The medication provides the appetite suppression -- you provide the lifestyle foundation that makes the weight loss stick.
Read more:
Ozempic Complete Guide | Mounjaro SA Guide | GLP-1 Guide | Weight Loss Injections SA